

# MOLECULAR CANCER THERAPEUTICS

# TABLE OF CONTENTS

## HIGHLIGHTS

**1217** Selected Articles from This Issue

## FIRST DISCLOSURE

**1219** **Pretargeted Radioimmunotherapy with the Novel Anti-oxMIF/HSG Bispecific Antibody ON105 Results in Significant Tumor Regression in Murine Models of Cancer**

Alejandro A. Puchol Tarazona, Alexander Schinagl, Irina Mirkina, Gregor Rossmueller, Randolph J. Kerschbaumer, Friedmund Bachmann, and Michael Thiele

## SMALL MOLECULE THERAPEUTICS

**1230** **Radiation and Chemo-Sensitizing Effects of DNA-PK Inhibitors Are Proportional in Tumors and Normal Tissues**

Jennifer H.E. Baker, Alastair H. Kyle, Nannan A. Liu, Taixiang Wang, Xinhui Liu, Sevin Teymori, Judit P. Banáth, and Andrew I. Minchinton

**1241** **A Senescence-Mimicking (Senomimetic) VEGFR TKI Side Effect Primes Tumor Immune Responses via IFN/STING Signaling**

Melissa Dolan, Yuhao Shi, Michalis Mastro, Mark D. Long, Amber McKenry, James W. Hill, Cristina Vaghi, Sebastien Benzekry, Joseph Barbi, and John M.L. Ebos

**1261** **MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in *NF1*-Deficient Glioblastoma**

Maria Ioannou, Kriti Lalwani, Abiola A. Ayanlaja, Viveka Chinnasamy, Christine A. Pratilas, and Karisa C. Schreck

**1273** **Combination Immunotherapy with Vaccine and Oncolytic HSV Virotherapy Is Time Dependent**

Stacie K. Totsch, Andrew S. Ishizuka, Kyung-Don Kang, Sam E. Gary, Abbey Rocco, Aaron E. Fan, Li Zhou, Pablo A. Valdes, SeungHo Lee, Jason Li, Luca Peruzzotti-Jametti, Sarah Blitz, Christopher M. Garliss, James M. Johnston, James M. Markert, Geoffrey M. Lynn, Joshua D. Bernstock, and Gregory K. Friedman

## LARGE MOLECULE THERAPEUTICS

**1282** **MYTX-011: A pH-Dependent Anti-c-MET Antibody-Drug Conjugate Designed for Enhanced Payload Delivery to c-MET-Expressing Tumor Cells**

Nimish Gera, Kyle M. Fitzgerald, Vijay Ramesh, Purvi Patel, Deepak Kanojia, Federico Colombo, Lena Kien, Simon Aoyama, Lihui Xu, Jussekia Jean, Amit M. Deshpande, William C. Comb, Thomas Chittenden, and Brian P. Fiske

**1294** **HPN328, a Trispecific T Cell-Activating Protein Construct Targeting DLL3-Expressing Solid Tumors**

Mary E. Molloy, Wade H. Aaron, Manasi Barath, Mabel C. Bush, Evan C. Callihan, Kevin Carlin, Michael Cremin, Thomas Evans, Maria G. Guerrero, Golzar Hemmati, Avneel S. Hundal, Llewelyn Lao, Payton Laurie, Bryan D. Lemon, S.J. Lin, Jessica O'Rear, Purbasa Patnaik, Sony Sotelo Rocha, Linda Santiago, Kathryn L. Strobel, Laura B. Valenzuela, Chi-Heng Wu, Stephen Yu, Timothy Z. Yu, Banmeet S. Anand, Che-Leung Law, Liping L. Sun, Holger Wesche, and Richard J. Austin

**1305** **IL-15/IL-15R $\alpha$ -Fc-Fusion Protein XmAb24306 Potentiates Activity of CD3 Bispecific Antibodies through Enhancing T-Cell Expansion**

Ji Li, Robyn Clark, Dionysos Slaga, Kendra Avery, Ke Liu, Suzanne Schubbert, Rajat Varma, Eugene Chiang, Klara Totpal, Matthew J. Bennett, Patrick G. Holder, and Teemu T. Junttila

**1317** **Enhancing Neutrophil Cytotoxicity of a Panel of Clinical EGFR Antibodies by Fc Engineering to IgA3.0**

Chilam Chan, J.H. Marco Jansen, Ilona S.T. Hendriks, Ida C. van der Peet, Meggy E.L. Verdonshot, Elsemieke M. Passchier, Maria Tsioumppekou, Maaïke Nederend, Sharon A. Klomp, Thomas Valerius, Matthias Peipp, Jeanette H.W. Leusen, and Patricia A. Olofsen

## TARGETING DRUG RESISTANCE

**1332** **Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation**

Lily L. Nguyen, Zachary L. Watson, Raquel Ortega, Elizabeth R. Woodruff, Kimberly R. Jordan, Ritsuko Iwanaga, Tomomi M. Yamamoto, Courtney A. Bailey, Francis To, Abigail D. Jeong, Saketh R. Guntupalli, Kian Behbakht, Veronica Gibaja, Nausica Arnoult, Alexis Coccozaki, Edward B. Chuong, and Benjamin G. Bitler

# TABLE OF CONTENTS

## COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

- 1348**    **Prognostic Significance of SASP-Related Gene Signature of Radiation Therapy in Head and Neck Squamous Cell Carcinoma**  
Min Kyeong Lee, Seon Rang Woo, Joo Kyung Noh, Soonki Min, Moonkyoo Kong, Young Chan Lee, Seong-Gyu Ko, and Young-Gyu Eun


## CORRECTION

- 1360**    **Correction: Oleanolic Acid Inhibits Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma by Promoting iNOS Dimerization**  
Hongzhi Wang, Weilong Zhong, Jianmin Zhao, Heng Zhang, Qiang Zhang, Yuan Liang, Shuang Chen, Huijuan Liu, Shumin Zong, Yixuan Tian, Honggang Zhou, Tao Sun, Yanrong Liu, and Cheng Yang

## ABOUT THE COVER

PreTarg-it employs a two-step process for targeted delivery of radioactivity to tumors. First, a bispecific antibody (“Compound 1”) targets a specific tumor antigen with one arm. Once it localizes in the tumor and clears from the bloodstream, a radiolabeled small ligand (“Compound 2”) is administered. The radioligand binds to the antibody’s second arm in the tumor, while unbound radioligand is quickly excreted. This minimizes radioactivity exposure to healthy organs and achieves high therapeutic indexes. See graphical abstract and the full article on page 1219.

doi: 10.1158/1535-7163.MCT-23-9-CVR



**NOTICE:** This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to <https://aacrjournals.org/pages/editorial-policies#coi>.